Brief: Firebrick Pharma Ltd Says Nasodine Covid-19 Patent Granted In South Africa
29/11/2023 01:36
Nov 29 (Reuters) - Firebrick Pharma Ltd FRE.AX :
* NASODINE COVID-19 PATENT GRANTED IN SOUTH AFRICA
Source text for Eikon: ID:nASXc0cWjl
Further company coverage: FRE.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Firebrick Pharma
See all newsAustralia's Firebrick Pharma jumps on plan to launch Nasodine products in US retail market
Brief: Firebrick Pharma Receives A$293,000 Research And Development Tax Incentive
Brief: Firebrick Pharma Says Nasodine Composition Patent Granted In New Zealand
Brief: Firebrick Pharma Says Nasodine Patent Accepted In Canada
Brief: Firebrick Pharma Secures A$1.5 Million Via Placement